Results 181 to 190 of about 557,072 (313)
Abstract Background In modern medicine the concept of wellness is often accompanied by various misconceptions arising from several factors, including a lack of clear definitions, the commercialization of wellness, and prevailing biases and stereotypes.
Indu Subramanian +40 more
wiley +1 more source
Low Rate of Germline Investigation for Variants of Suspected Germline Origin Detected During the Diagnostic Work-Up of Myeloid Neoplasms. [PDF]
Al-Djaber A +7 more
europepmc +1 more source
Abstract Background As Parkinson's disease (PD) progresses, motor fluctuations become increasingly difficult to manage with oral medications. Foslevodopa/foscarbidopa (LDp/CDp), delivered as a continuous 24‐h/day subcutaneous infusion, offers continuous levodopa delivery and stable plasma levodopa levels that reduce motor fluctuations. LDp/CDp has been
K. Ray Chaudhuri +20 more
wiley +1 more source
Bipolar Disorder as a Long‐Term Risk Factor for Parkinson's Disease: A Nationwide Case–Control Study
Abstract Background Previous studies suggest an association between bipolar disorder (BD) and an increased risk of Parkinson's disease (PD), but the long‐term temporal relationship remains unclear. Particularly, it is unclear whether the risk of PD is influenced by the duration since BD diagnosis.
Elina Jaakkola +5 more
wiley +1 more source
Nordic Respiratory Academy: a historical note and reflection. [PDF]
Gulsvik A, Bakke PS, Stavem K.
europepmc +1 more source
Monoaminergic Networks of Cognitive and Behavioral Symptoms in Early Parkinson's Disease
Abstract Background Parkinson's disease (PD) is associated with several behavioral and cognitive symptoms, the neurobiological background of which is not yet fully understood. Objectives The aim was to investigate the association between monoamine function and four specific nonmotor symptoms in early PD using the Parkinson's Progression Markers ...
Kalle J. Niemi +3 more
wiley +1 more source
Normality, Belonging and Welfare Inclusion among Young People with Drug Problems: A Commentary. [PDF]
Sylvin MG.
europepmc +1 more source

